Use of Pyridostigmine for Constipation in Diabetics

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Adil Bharucha, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00276406
First received: January 11, 2006
Last updated: November 2, 2012
Last verified: November 2012
  Purpose

Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the speed at which food travels through the stomach, intestines and colon, and if pyridostigmine improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed in this study is considered investigational.


Condition Intervention Phase
Constipation
Diabetes Mellitus
Colonic Transit
Gastric Emptying
Drug: Pyridostigmine
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pyridostigmine in Diabetics With Constipation: Randomized, Placebo-controlled, Double-blind Trial

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy [ Time Frame: Baseline period (days 7-9 ), Treatment period (days 14-17) ] [ Designated as safety issue: No ]
    The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images of the abdomen are taken hourly for the first 6 hours after the radio-labeled meal, then at 8, 24 and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. GC24 is the measurement taken at 24 hours after the radio-labeled meal.

  • Ascending Colon Emptying Half-time (AC t1/2) Measured in Hours [ Time Frame: Baseline period (days 7-9 ), Treatment period (days 14-17) ] [ Designated as safety issue: No ]
    Calculated by linear interpolation of values on the AC emptying curve.


Secondary Outcome Measures:
  • Gastric Emptying Half-time (GE t1/2) [ Time Frame: Baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    The measure of time for 50 percent of a radio-labeled meal to empty from the stomach.

  • Colonic Filling at 6 Hours [ Time Frame: Baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    The proportion of a radio-labeled meal in the colon at 6 hours (identifiable by radio-labelled tracer to capsule eaten with meal), measured by scintigraphy. This is an indirect measurement of small-bowel transit time.

  • Colonic Geometric Center at 48 Hours (GC48) as Measured by Scintigraphy [ Time Frame: Baseline period (days 7-9 ), Treatment period (days 14-17) ] [ Designated as safety issue: No ]
    The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly for the first 6 hours after the radio-labeled meal, then at 8, 24 and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. GC48 is the measurement taken at 48 hours after the radio-labeled meal.

  • Stool Frequency Per Day [ Time Frame: Daily during baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    During 9 days of the baseline period and during 17 days of the treatment period, subjects used a daily diary to record the number of times per day they had a bowel movement. Only the 7 days of highest treatment dose will be used for comparison purposes.

  • Stool Form/Consistency [ Time Frame: Daily during baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    During 9 days of the baseline period and during 17 days of the treatment period, subjects used a daily diary to record a description of stool consistency according to the Bristol Stool Form Scale (ranging from 1 (hard lumps) to 7 (watery)). The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.

  • Stool Ease of Passage [ Time Frame: Daily during baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    During 9 days of the baseline period and during 17 days of the treatment period, subjects used a daily diary to record a description of stool ease of passage of stool, according to the Bristol Stool Form Scale (ranging from 1 (manual disimpaction) to 7 (incontinence)). Only the 7 days at highest treatment dose will be used for comparison purposes.

  • Sense of Completely Emptying Bowels [ Time Frame: Daily during baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    During 9 days of the baseline period and during 17 days of the treatment period, subjects used a daily diary to record whether or not they felt they had completely emptied their bowels(1= Yes; 0= No). Only the 7 days of highest treatment dose will be used for comparison purposes.

  • Stool Frequency Per Week [ Time Frame: Daily during baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: No ]
    During 9 days of the baseline period and during 17 days of the treatment period, subjects used a daily diary to record the number of times per day they had a bowel movement. Complete spontaneous bowel movements per week are reported. Only the 7 days of highest treatment dose will be used for comparison purposes.

  • Heart Rate Before and After Treatment [ Time Frame: Baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: Yes ]
    Heart rate is the number of beats per minute, as recording on an Electrocardiogram (ECG).

  • QTc Interval Before and After Treatment [ Time Frame: Baseline period (9 days), Treatment period (7 days) ] [ Designated as safety issue: Yes ]
    The corrected QT interval (QTc) is a measurement of time (seconds) between the Q and T waves of an heart beat as recorded during an Electrocardiogram (ECG).


Enrollment: 30
Study Start Date: May 2006
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pyridostigmine
Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
Drug: Pyridostigmine
Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Other Name: Mestinon
Placebo Comparator: Placebo
Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
Drug: Placebo
If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.

Detailed Description:

Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors increase colonic motility. The study evaluated the effects of a cholinesterase inhibitor (pyridostigmine vs. placebo) on gastrointestinal and colonic transit and bowel function in diabetic patients with constipation.

After a 9-day baseline period, patients with diabetes mellitus and chronic constipation without defecatory disorder will be randomized to oral placebo or pyridostigmine, starting with 60 mg three times a day, increasing by 60 mg every third day up to the maximum tolerated dose of 120 mg three times a day; this dose will be maintained for 7 days. Gastrointestinal and colonic transit (assessed by scintigraphy) and bowel function will be evaluated at baseline and the final 3 and 7 days of treatment, respectively.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with diabetes mellitus (Type I or type II), diagnosed by a physician.
  • On medical treatment for diabetes (oral medication or injected insulin) for at least one year
  • Symptomatic constipation at least 25% of the time in the past year (Rome II criteria for functional constipation)
  • 18-70 years of age
  • Colonoscopy negative for obstructive lesions, cancer, or inflammatory bowel disease (IBS) within the last 8 years if 50 years of age or older
  • Able to provide written informed consent before participating in trial
  • Able to communicate adequately with the Investigator and to comply with the requirements for the entire study

Exclusion Criteria:

  • History of pelvic floor dysfunction (other functional GI disorders, eg IBS, non-ulcer dyspepsia are acceptable); Specifically, patients will be excluded if they have at least 2 of the following 3 criteria:

    • History of digital evacuation of the rectum or pressure on the posterior aspect of the vagina or perineum to facilitate defecation
    • Examination findings suggestive of puborectalis spasm or anismus, on assessment by an experienced gastroenterologist with expertise in this field; i.e. high anal sphincter tone at rest, failure of perineal descent by >1cm on straining, and tenderness or paradoxical contraction of the puborectalis on digital examination
    • Requirement of > 200g to expel a rectal balloon during voluntary straining
  • Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, tubal ligation, or inguinal hernia repair
  • Suspected or known gastrointestinal or genitourinary obstruction
  • Uncontrolled hypertension (defined as > 150/90 at rest)
  • Known cardiac arrhythmia or ECG abnormalities, i.e. cardiac conduction disturbances (2nd or 3rd degree atrioventricular (AV) block, prolonged corrected QT interval (QTc)(> 460 msec) or bradycardia (< 45 beats/minute))
  • Renal insufficiency with serum creatinine greater than 2 mg/dl based on a reading from the previous 6 months
  • Asthma or chronic obstructive pulmonary disease requiring systemic steroids in the previous 3 years (inhaled steroids acceptable)
  • Current use of narcotics, gut prokinetic drugs (eg metoclopramide, domperidone, tegaserod, senekot), anticholinergic medication (eg. Hyoscyamine, belladonna), antidiarrheals (Imodium, Lomotil), or laxatives other than fiber supplements, docusate, or glycerin suppositories. Patients on any of these restricted medications must cease use at least 48 hours before starting and for the duration of both study phases. No rescue laxatives will be permitted within 7 days of transit testing
  • Patients who have taken any investigational medications within the past 30 days
  • Known intolerance or allergy to eggs
  • Pregnant or breast-feeding females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00276406

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Adil E. Bharucha, MBBS, MD Mayo Clinic
  More Information

Additional Information:
Publications:
Responsible Party: Adil Bharucha, MD, Professor of Medicine, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00276406     History of Changes
Other Study ID Numbers: 05-004037, UL1RR024150-01, P01DK068055
Study First Received: January 11, 2006
Results First Received: November 2, 2012
Last Updated: November 2, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus
Constipation
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Pyridostigmine Bromide
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 30, 2014